<DOC>
	<DOCNO>NCT00496353</DOCNO>
	<brief_summary>The purpose phase I portion ; 1 ) evaluate safety tolerability MK2461 2 ) determine recommend phase 2 dose dos MK2461 . The purpose phase II portion evaluate anti-tumor efficacy MK2461 .</brief_summary>
	<brief_title>MK2461 Phase I/II Study Patients With Advanced Solid Tumors ( MK-2461-002 AM1 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<criteria>Patients must least 18 year age , adequate organ function , ecog performance &lt; 2 No chemotherapy , radiotherapy , biological therapy 4 week study participation Patients must primary central nervous system tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Neoplasm Malignant</keyword>
</DOC>